Global Hunter Securities Starts ImmunoCellular Therapeutics (IMUC) at Buy; Compelling Value Proposition in Cancer Immunotherapy Group
Tweet
Share
E-mailGet Alerts IMUC Hot Sheet
Price: $0.20 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 8
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 8
Join SI Premium – FREE
Global Hunter Securities initiates coverage on ImmunoCellular Therapeutics (OTC: IMUC) with a Buy. PT $5.00.
Global analyst says, "IMUC’s lead cancer vaccine, ICT-107, is a next-generation dendritic cell-based (DCB) vaccine comprised of six antigens found at high levels of expression in cancer stem cells (CSCs), and has demonstrated promising early data in GBM. Dendritic cell vaccines are made individually for a particular patient through an intensive procedure. Compared to the low yields and gross margins achieved with the manufacture of the DCB vaccine, Provenge, IMUC estimates much better economics with ICT-107, which could help the company realize a faster path to profitability. Based on a sensitivity analysis of discounted P/E multiples, we assigned a 25x P/E multiple to projected 2016 earnings per share of $0.89 discounted annually by 35%, and derived a fair value estimate for IMUC shares of $5."
For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.
Shares of ImmunoCellular Therapeutics closed at $1.43 yesterday.
Global analyst says, "IMUC’s lead cancer vaccine, ICT-107, is a next-generation dendritic cell-based (DCB) vaccine comprised of six antigens found at high levels of expression in cancer stem cells (CSCs), and has demonstrated promising early data in GBM. Dendritic cell vaccines are made individually for a particular patient through an intensive procedure. Compared to the low yields and gross margins achieved with the manufacture of the DCB vaccine, Provenge, IMUC estimates much better economics with ICT-107, which could help the company realize a faster path to profitability. Based on a sensitivity analysis of discounted P/E multiples, we assigned a 25x P/E multiple to projected 2016 earnings per share of $0.89 discounted annually by 35%, and derived a fair value estimate for IMUC shares of $5."
For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.
Shares of ImmunoCellular Therapeutics closed at $1.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
- Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
- Choice Hotels (CHH) PT Lowered to $137 at Baird
Create E-mail Alert Related Categories
New CoverageRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
